{"organizations": [], "uuid": "4c3f6e30ef3f4f6861dec46d44cd547a55d072dc", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "//sc.cnbcfm.com/applications/cnbc.com/staticcontent/img/cnbc_logo.gif", "site_section": "http://www.cnbc.com/id/10000027", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/01/04/globe-newswire-obalon-schedules-fourth-quarter-and-full-year-2017-preliminary-unaudited-revenue-and-business-update-conference-call-for.html", "country": "US", "domain_rank": 767, "title": "Obalon Schedules Fourth Quarter and Full Year 2017 Preliminary, Unaudited Revenue and Business Update Conference Call for January 5, 2018 at 8:30 a.m. Eastern Time", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.008, "site_type": "news", "published": "2018-01-05T01:15:00.000+02:00", "replies_count": 0, "uuid": "4c3f6e30ef3f4f6861dec46d44cd547a55d072dc"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/01/04/globe-newswire-obalon-schedules-fourth-quarter-and-full-year-2017-preliminary-unaudited-revenue-and-business-update-conference-call-for.html", "ord_in_thread": 0, "title": "Obalon Schedules Fourth Quarter and Full Year 2017 Preliminary, Unaudited Revenue and Business Update Conference Call for January 5, 2018 at 8:30 a.m. Eastern Time", "locations": [], "entities": {"persons": [], "locations": [{"name": "san diego", "sentiment": "none"}, {"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "obalon therapeutics, inc.", "sentiment": "neutral"}, {"name": "pacific time", "sentiment": "none"}, {"name": "eastern time", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "SAN DIEGO, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced that it plans to release its preliminary, unaudited revenue for the fourth quarter and full year 2017 before the market opens on Friday, January 5, 2018.\nThe company will hold a conference call and simultaneous webcast at 8:30 AM, Eastern Time (5:30 AM, Pacific Time) on Friday, January 5, 2018 to discuss the company's preliminary, unaudited revenue results and provide a business update. Interested parties may access the conference call by dialing (844) 889-7791 (U.S.) or (661) 378-9934 (international) using passcode 1386606. Media and individuals will be in a listen-only mode. Participants are asked to dial in a few minutes prior to the call to register for the event. The conference call will also be webcast live at: http://edge.media-server.com/m6/p/q46j6onn .\nAn archive of the webcast will be available for twelve months following the event on the Obalon Therapeutics website located at http://investor.obalon.com in the “News & Events” section.\nAbout Obalon Therapeutics, Inc.\nObalon Therapeutics, Inc. (NASDAQ:OBLN) is a San Diego-based company focused on developing and commercializing novel technologies for weight loss. The Obalon management team has over 150 combined years of experience in developing and commercializing novel medical technologies with a track record of financial and clinical excellence. For more information, please visit www.obalon.com .\nFor Obalon Therapeutics, Inc.\nInvestor Contact:\nWilliam Plovanic\nChief Financial Officer\nObalon Therapeutics, Inc.\nOffice: +1 760 607 5103\nwplovanic@obalon.com\nMedia:\nMegan Driscoll\nEvolveMKD\nOffice Phone: +1 646 517 4220\nmdriscoll@evolvemkd.com\nSource:Obalon Therapeutics, Inc.", "external_links": ["https://www.globenewswire.com/Tracker?data=0Vqr2Leu6SBnJZKjkIPWN8SAU6WxBwLZgaqbPj9hrFd49B97Q61PjYWDwS9QNPAObO8RVG5CAW4iH36inQHH8t_XwxP8gtM46NqxBWaMqUo=", "http://edge.media-server.com/m6/p/q46j6onn", "https://www.globenewswire.com/Tracker?data=Z_GHz-FKBCZWUH_PYhGHDGUAcA3JFtDmL2qq0xIZD4fT041wLkc1rv2CFD9aAfJCba_ftZBmzu4zbIFCCSkNMrGA6yezJTC35oypbxcqZDw=", "https://www.globenewswire.com/Tracker?data=e-PJiaKOF3bgylcWcQMwUq-FdOCUohCch3YCAolK-qUxlFKQsb2BPb3S4RdUOca9ahU83FxiQ-29lO9aEWHnw_dpxNFkKwDhWEGKbY80--4=", "https://www.globenewswire.com/NewsRoom/AttachmentNg/e02ca260-1349-45d0-a97e-755cdb8403b4", "https://www.globenewswire.com/Tracker?data=scMOaPyLVZYVbwAxLgYXLNtloH-VGMqR3DAQ_bGBJcgYXSxrcBfc1HEFrb9OvD3TNt6DW8CMa9p_3pkyOhnMDg==", "https://www.globenewswire.com/Tracker?data=0Vqr2Leu6SBnJZKjkIPWN3wx2MMa3u9aMMgoh3t0ZtiaLagfyuXX1CrlXQRwgfsEnx2jh2nH5dFHj5cgUITsyYNO32Z6ZB57vds1F_2E53eh8agB65Ed0WW18r6PUusd4EViTR_NJgCnYw4lno9tVQ=="], "published": "2018-01-05T01:15:00.000+02:00", "crawled": "2018-01-05T01:22:14.009+02:00", "highlightTitle": ""}